Research programme: small molecule therapeutics - MDI Therapeutics/University of Michigan
Alternative Names: MDI 2268Latest Information Update: 28 Apr 2023
Price :
$50 *
At a glance
- Originator University of Michigan
- Developer MDI Therapeutics; University of Michigan
- Class Antifibrotics; Antithrombotics; Small molecules
- Mechanism of Action Plasminogen activator inhibitor-1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Arterial thrombosis; Pulmonary fibrosis; Venous thrombosis
Most Recent Events
- 28 Apr 2023 No recent reports of development identified for preclinical development in Arterial-thrombosis in USA (PO)
- 28 Apr 2023 No recent reports of development identified for preclinical development in Pulmonary-fibrosis in USA (PO)
- 28 Apr 2023 No recent reports of development identified for preclinical development in Venous-thrombosis in USA (PO)